Abstract
Advanced Glycation Endproducts (AGEs) are a group of heterogeneous compounds formed by the non enzymatic reactions between aldehydic group of reducing sugars with proteins, lipids or nucleic acids. Formation and accumulation of AGEs are related with the aging process and are accelerated in diabetes. Type 2 diabetes are the most common form of diabetes, which are characterized by hyperglycemia and insulin resistance associated to a progressive deterioration of beta cell function and mass. The pathogenic role of AGEs in vascular diabetic complications is widely recognised. Recently, other aspects of the detrimental effects of AGEs in type 2 diabetes have emerged: AGEs interfere with the complex molecular pathway of insulin signalling, leading to insulin resistance; AGEs modify the insulin molecule, and consequently, its function; AGEs decrease insulin secretion and insulin content. In this article, we review the role of AGEs in type 2 diabetes, beyond their involvement in vascular complications.
Keywords: Diabetes, advanced glycation end products, pancreatic β-cells, insulin resistance, metabolic syndrome, hyperglycemia, glucose homeostasis, methylglyoxal, glycolaldehyde, AGE pentosidine, phosphorylation, musculoskeletal tissues
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications
Volume: 11 Issue: 2
Author(s): Alessandra Puddu and Giorgio L. Viviani
Affiliation:
Keywords: Diabetes, advanced glycation end products, pancreatic β-cells, insulin resistance, metabolic syndrome, hyperglycemia, glucose homeostasis, methylglyoxal, glycolaldehyde, AGE pentosidine, phosphorylation, musculoskeletal tissues
Abstract: Advanced Glycation Endproducts (AGEs) are a group of heterogeneous compounds formed by the non enzymatic reactions between aldehydic group of reducing sugars with proteins, lipids or nucleic acids. Formation and accumulation of AGEs are related with the aging process and are accelerated in diabetes. Type 2 diabetes are the most common form of diabetes, which are characterized by hyperglycemia and insulin resistance associated to a progressive deterioration of beta cell function and mass. The pathogenic role of AGEs in vascular diabetic complications is widely recognised. Recently, other aspects of the detrimental effects of AGEs in type 2 diabetes have emerged: AGEs interfere with the complex molecular pathway of insulin signalling, leading to insulin resistance; AGEs modify the insulin molecule, and consequently, its function; AGEs decrease insulin secretion and insulin content. In this article, we review the role of AGEs in type 2 diabetes, beyond their involvement in vascular complications.
Export Options
About this article
Cite this article as:
Puddu Alessandra and L. Viviani Giorgio, Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187153011795564115
DOI https://dx.doi.org/10.2174/187153011795564115 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotrophic Factors for Retinal Ganglion Cell Neuropathy - With a Special Reference to Diabetic Neuropathy in the Retina
Current Diabetes Reviews Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Glycation of Human Serum Albumin in Diabetes: Impacts on the Structure and Function
Current Medicinal Chemistry QSAR, Docking and Molecular Fragment Replacement Study based on a Conformation- Independent Approach on Trifluorophenyl β-aminoamide derivatives as DPP IV Inhibitors
Current Enzyme Inhibition Animal Models for Testing Anti-Prion Drugs
Current Topics in Medicinal Chemistry CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Glutamatergic Neurotransmission As Molecular Target of New Anticonvulsants
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Regenerative Medicine Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials
Current Clinical Pharmacology Cytokine-Induced Depression: Current Status and Novel Targets for Depression Therapy
CNS & Neurological Disorders - Drug Targets The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Clinical Relevance of Non-Fasting and Postprandial Hypertriglyceridemia and Remnant Cholesterol
Current Vascular Pharmacology Rapid and Solventless Analysis of Polychlorinated Biphenyls in Packaged Milk Using Gas Chromatography
Current Chromatography The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) In Vivo Angiogenesis and Lymphangiogenesis Models
Current Molecular Medicine Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Predicting Factors Affecting Glucose Monitoring Treatment Satisfaction and Drug Attitude Inventory (Adherence) Among Patients with Type 2 Diabetes Mellitus; Cross-sectional Observational Study
Current Diabetes Reviews